Incidence of Epstein–Barr virus in Syrian women with breast cancer: A tissue microarray study

Figures & data

Table 1. The specific primer sets for LMP1 and EBNA1 genes of EBV used for PCR amplification

Genes	Primers
LMP1	5'- TTGGAGATTCTCTGGCGACT -3'
	5'- AGTCATCGTGGTGGTGTTCA -3'
EBNA1–297	5'- AAGGAGGGTGGTTTGGAAAG -3'
	5'- AGACAATGGACTCCCTTAGC -3'
EBNA1–207	5'- ATCGTGGTCAAGGAGGTTCC -3'
	5'- ACTCAATGGTGTAAGACGAC -3'
GAPDH	5'- GAAGGC-CATGCCAGTGAGCT -3'
	5'- CCGGGAAACTGTGGCGTGAT -3'

Table 2A. EBV detection in breast carcinomas by PCR. The incidence of this virus was found in 58 samples out of 108 examined using specific primers for LMP1 and EBNA1 genes of EBV

	Tested cases	Positive	Percentage
Breast cancer tissues	108	56	51.85
Table 2B. Presence of EBV and its association with invasive breast cancer phenotype. The presence of EBV is more frequent in invasive breast cancer in comparison to In Situ breast cancer tissues (P = 0.0013); the presence of EBV was assessed by PCR for LMP1 and EBNA1 genes and confirmed by IHC analysis of LMP1 expression using Tissue Microarray (TMA) methodology, as described in the Materials and Methods section.
Breast cancer	No of cases	EBV+(%)
Invasive	84	51/84 (60.7)
In situ	24	5/24 (20.8)

Figure 1. Representative IHC revealing LMP1 expression of EBV in 2 invasive breast cancer tissue samples (A): with LMP1 antibody; (B): without antibody, control). Magnification is 100X. This analysis was performed using TMA methodology with all the necessary controls; and presence of EBV was confirmed by PCR using specific primers for LMP1 and EBNA1 genes in 54 cases of our samples including these samples.

Figure 2. Representative PCR reactions for LMP1 of EBV in 13 different breast cancer tissue samples. LMP1 and EBNA1 are present in 8 of 13 samples (line 1: Mec1 cell line was used as a positive control; MCF7 and normal mammary epithelial cells were used as negative controls, data not shown).